

Press release – August 26, 2021

Patent approval in Europe completes strong worldwide IP protection of BioXmark® as a unique liquid fiducial marker

- **BioXmark® and essential parts of the carbohydrate technology behind the product are now covered by solid patent protection in 23 jurisdictions, including Europe, the US, Japan and China**
- **BioXmark® is CE-marked and commercially available in Europe to radiographically mark soft tissue and open new opportunities for high precision cancer radiation therapy**

DK-Copenhagen – Nanovi is pleased to inform that the company has met an important milestone with the European Patent Office's (EPO) approval and issuance of patent no. 3003397. The patent, entitled "Gel formulations for guiding radiation therapy", provides full protection for the unique composition of BioXmark® and other related radiographic marker compositions as well as for their use to guide high precision radiation therapy. The process of patent validation into relevant European countries has been completed.

BioXmark® is a liquid fiducial marker with unique features to open new opportunities in the field of high precision cancer radiation therapy. BioXmark® was invented by the Department of Health Technology at the Technical University of Denmark (DTU) in collaboration with Nanovi, who has developed and is commercializing the product in Europe. Preparations for submission of BioXmark® for US clearance are ongoing.

The recently issued European patent completes the core of a family of at the moment 23 granted patents, when including the validations in Europe, ensuring protection of BioXmark® until at least 2033 in key markets worldwide, including Europe, the US, Japan and China.

The successful establishment of a strong worldwide patent protection for BioXmark® represents a major achievement for Nanovi's IP strategy, aiming to build full protection for the company's unique carbohydrate technology and specific compositions of liquid implantable medical devices as well as ensure freedom-to-operate in all target markets. Nanovi's patent portfolio currently counts six patent families and a total of 45 patents and patent applications. All patents are assigned jointly to DTU and Nanovi as co-owners, while worldwide development and commercialization rights are licensed exclusively to Nanovi.

In a comment to the European patent approval, Nanovi's CEO Jesper Boysen highlighted:

"The European patent approval is the ultimate proof of the unique and innovative profile of BioXmark®, and it completes the core of our patent protection for this liquid fiducial marker worldwide. Following CE-marking and launch of BioXmark in 2020, we are expanding our user network - and working with some of the most prominent hospitals and radiation oncology specialists, we continue to uncover new application opportunities for BioXmark® to guide high precision cancer therapy."

**Nanovi contact:**

Jesper Boysen, CEO

Phone: +45 24 65 60 33

E-mail: jb@nanovi.com

About Nanovi

Nanovi A/S is a Danish medical device company specialized in precision marking for better cancer therapy. Our corporate dedication is to empower healthcare professionals with the best possible tools to expand their options for the delivery of high precision radiation therapy and surgery for the benefit of cancer patients and to support healthcare efficiency.

Nanovi has a portfolio of unique in-house developed liquid fiducial markers for both human and veterinary use and a pipeline of new product candidates.

All our products are derived from a patented carbohydrate technology system, co-invented with and licensed from the Department of Health Technology at the Technical University of Denmark, DTU.

For more information, please visit: www.nanovi.com – and follow us on [LinkedIn](#)